Product information and disease descriptionProduct descriptionProduct information
Product comparison
10 evidence topics · 16 sources
APOL1-directed and other investigational therapies for AMKD: review table
“Antisense oligonucleotide therapy is in phase 1 trials because of studies in mice showing a dose-dependent reduction in liver and kidney APOL1 mRNA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“a recent small molecule inhibitor, MZE829, attempts to phenocopy this protective variant in a phase 1 study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MZE829 (Maze Therapeutics): oral dual-mechanism APOL1 inhibitor, phase 2 HORIZON interim results
MZE829: HORIZON enrollment completed and pivotal trial planned for the first half of 2027
Competitive positioning of inaxaplin and MZE829
AZD2373 (AstraZeneca): subcutaneous APOL1-directed therapy, phase 2b APPRECIATE trial
| Field | Quoted record |
|---|---|
| Sponsor | “AstraZeneca” |
| Status | “Active, not recruiting” |
| Enrollment (actual) | “63” |
| Primary completion (estimated) | “2027-10-04” |